
Commentary|Articles|September 23, 2025
Myeloma Experts Summarize Key Themes From the 22nd Annual IMS Meeting and Exposition
Author(s)Ashling Wahner
Fact checked by: Kyle Doherty
OncLive heard from myeloma experts about the biggest developments in the field at the 22nd Annual International Myeloma Society Meeting and Exposition.
Advertisement
Advertisement
The
Related to this article

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The FDA approved iberdomide plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma.

Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.

Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Advertisement
Advertisement


